# A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

> **NCT00040092** · PHASE3 · COMPLETED · sponsor: **Aptose Biosciences Inc.** · enrollment: 400 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Virulizin®

## Key facts

- **NCT ID:** NCT00040092
- **Lead sponsor:** Aptose Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2008-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040092, "A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00040092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*